药物信息为Valturna (aliskiren and valsartan, USP) TabletsInitial U.S. Approval: 2009 (Novartis Pharmaceuticals Corporation): WARNING: AVOID USE IN PREGNANCY
- WARNING: AVOID USE IN PREGNANCY
- 1 INDICATIONS AND USAGE
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
- 7 DRUG INTERACTIONS
- 10 OVERDOSAGE
- 11 DESCRIPTION
- 14 CLINICAL STUDIES
- 16 HOW SUPPLIED/STORAGE AND HANDLING
- 外部链接相关的Valturna (aliskiren and valsartan, USP) TabletsInitial U.S. Approval: 2009 (Novartis Pharmaceuticals Corporation)
When pregnancy is detected, discontinue Valturna as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin-aldosterone system can cause injury and death to the developing fetus. [See Warnings and Precautions (5.1)].
- Drug Information Provided by National Library of Medicine (NLM).
这个站点被设计主要作为提示系统供合格的医师和其他医疗专家使用。 通过使用这个站点您了解并且接受DiagnosisPro.com不会使用作为一个诊断决策系统，并且不能使用做一个临床诊断或替换或者否决一位被准许的医疗保健专家的评断或临床诊断 (充分的使用条款). 我们遵循健康网络基金会的 医学和健康网站的行为准则. 点击这里核实
© 2012 MedTech USA, Inc. (最后更新在05/25/12)
